Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

September 30, 2026

Study Completion Date

October 31, 2026

Conditions
Lung Cancer
Interventions
DRUG

IRDye800CW-nimotuzumab

50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion

Trial Locations (1)

S7M 0Z9

RECRUITING

St. Paul's Hospital, Saskatoon

All Listed Sponsors
collaborator

Western Economic Diversification Canada

OTHER_GOV

lead

University of Saskatchewan

OTHER